Jay S. Duker, MD, Director of the New England Eye Center, discusses the unmet need for patients with wet and dry macular degeneration. Dr. Duker discusses alternative forms of treatment currently in development including anti-PDGF agents and antioxidants within a patient’s diet.
Consulting Fees: Novartis, QLT, EMD Serono, ThromboGenics, Optos
Contracted Research: Carl Zeiss Meditec, Optovue
Ownership Interest: EyeNetra, Hemera, Ophthotech, Paloma